Shao-Lee Lin

SEC Form 4 insider

Chief Executive Officer · Cue Biopharma, Inc. ($CUE)

2 theses · first seen Aug 15, 2026

Window	Theses	Resolved	Wins	Win rate	Avg return	Median return
1d	0	0	0	—	—	—
3d	2	2	1	50%	-11.3%	-11.3%
1w	2	2	2	100%	-6.8%	-6.8%
1m	2	2	2	100%	+19.3%	+19.3%
3m	0	0	0	—	—	—
6m	0	0	0	—	—	—
1y	0	0	0	—	—	—

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$CUESEC 13Dbullish

Shao-Lee Lin · beneficial owner of Cue Biopharma, Inc. · 60d ago1 prior · awaiting results

Long 467,166 shares of CUE

467,166 shares · 6.2% of class · 2026-05-03

Schedule 13D: Shao-Lee Lin disclosed a stake in CUE

Shao-Lee Lin disclosed a 6.2% stake of 467,166 shares in Cue Biopharma, Inc. (CUE) in a Schedule 13D filed 2026-08-21.

At post $23.98Now $23.38-2.5% since postedas of Aug 24, 1:28 PM ET

1d—

3d-3.3%

1w+16.3%

1m+54.5%

3m—

6m—

1y—

View filing on SEC.gov →

$CUESEC Form 4bearish

Lin Shao-Lee · Chief Executive Officer at Cue Biopharma, Inc. · 67d ago1 prior · awaiting results

Sold 58,258 @ $27.58 avg · $1,606,562 · 2026-08-12

Form 4: Lin Shao-Lee sold CUE

Lin Shao-Lee (Chief Executive Officer at Cue Biopharma, Inc.) reported an open-market sale of 58,258 shares of CUE at an average $27.58, roughly $1,606,562, in a Form 4 filed 2026-08-14.

At post $34.20Now $23.38-31.6% since postedas of Aug 24, 1:28 PM ET

1d—

3d-19.2%

1w-29.9%

1m-16.0%

3m—

6m—

1y—

View filing on SEC.gov →

End of results.